Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human test of methylone for PTSD begins

NCT ID NCT06303648

Completed Knowledge-focused Sponsor: Transcend Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety and drug levels of methylone in 40 healthy volunteers aged 25 to 55. Participants received a single oral dose of methylone or a placebo. The study measured how the drug moves through the body and checked for side effects. This is a first step toward possibly using methylone to treat PTSD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
methylone
What this could lead to
If successful, this could pave the way for future studies testing methylone as a treatment for PTSD.
What could go wrong
This is a very early Phase 1 safety study in healthy people, not patients. It only measures drug levels and safety, not whether methylone works for PTSD. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Locations

  • CMAX Clinical Research

    Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.